Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Orvosi Hetilap
|
January 5, 2002
[Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease]
Z Barta, I Csípö, P Antal-Szalmás, et al.
Journal of Clinical Microbiology
|
November 8, 2003
Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures
L Majoros, G Kardos, A Belák, et al.
Lupus
|
December 17, 2009
Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus
Z Barta, M J Harrison, T Wangrangsimakul, et al.
Alimentary Pharmacology & Therapeutics
|
September 3, 2011
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L S Kiss, T Szamosi, T Molnar, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Orvosi Hetilap
|
January 5, 2002
[Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease]
Z Barta, I Csípö, P Antal-Szalmás, et al.
Journal of Clinical Microbiology
|
November 8, 2003
Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures
L Majoros, G Kardos, A Belák, et al.
Lupus
|
December 17, 2009
Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus
Z Barta, M J Harrison, T Wangrangsimakul, et al.
Alimentary Pharmacology & Therapeutics
|
September 3, 2011
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L S Kiss, T Szamosi, T Molnar, et al.
Page
of 2